Showing 5581-5590 of 5909 results for "".
- Rayner Launches New Eye Drop Formulations for Dry Eyehttps://modernod.com/news/rayner-launches-new-eye-drop-formulations-for-dry-eye/2476264/Rayner has introduced the AEON family of pre- and post-surgery eye drops to help patients with dry eye manage their condition and improve their visual outcomes. An instability in the tear film, caused by dry eye, has been shown to impact the preoperative biometry that can lead to incorrec
- Nidek Launches Upgraded AngioScan OCT-Angiography Softwarehttps://modernod.com/news/nidek-launches-upgraded-angioscan-oct-angiography-software/2476265/Nidek has announced the launch of new AngioScan upgraded OCT-Angiography software that enables visualization of retinal and choroidal microvasculature and blood flow using the RS-3000 Advance 2 OCT device. The
- FDA Approves Bausch + Lomb’s Lotemax SM For The Treatment Of Postoperative Inflammation And Painhttps://modernod.com/news/fda-approves-bausch-lombs-lotemax-sm-for-the-treatment-of-postoperative-inflammation-and-pain/2476267/Bausch + Lomb announced that the FDA has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery. Compared to Lotemax Gel 0.5%, Lotemax SM delivers a submicron particle size for faste
- EyeBrain Medical and IDOC Announce Partnership to Bring Neurolens to IDOC Independent Optometristshttps://modernod.com/news/eyebrain-medical-and-idoc-announce-partnership-to-bring-neurolens-to-idoc-independent-optometrists/2476270/IDOC and eyeBrain Medical announced a multiyear partnership to bring neurolens prescription lenses to all IDOC members across the United States. Neurolenses are the first and only prescription lenses that add a contoured prism to bring the eyes into alignment. Contoured prisms have been shown in
- Ocular Therapeutix Announces Dosing of First Patient in Phase 1 Clinical Trial for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-dosing-of-first-patient-in-phase-1-clinical-trial-for-the-treatment-of-wet-amd/2476273/Ocular Therapeutix announced the dosing of the first patient in a phase 1 trial of OTX-TKI (tyrosine kinase inhibitor implant) in patients with wet age-related macular degeneration (AMD). The first patient was dosed at the Sydney Retina Clinic in Sydney, Australia. “We are excited to annou
- ReNeuron Group Announces Positive Preliminary Data in US Retinitis Pigmentosa Trialhttps://modernod.com/news/reneuron-group-announces-positive-preliminary-data-in-us-retinitis-pigmentosa-trial/2476276/ReNeuron Group announced positive preliminary results in the company’s ongoing phase 1/2 clinical trial of its human retinal progenitor cells (hRPC) cell therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2 part of the trial have demonstrate
- Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for Xiperehttps://modernod.com/news/clearside-biomedical-receives-notification-of-fda-acceptance-of-nda-filing-for-xipere/2476281/Clearside Biomedical announced that the FDA has accepted for review the company’s new drug application (NDA) for Xipere (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection for the treatment of macular edema associated with uveitis. The FDA has determined that the ap
- New Medscape Report Finds More Than One in Three Doctors are Burned Outhttps://modernod.com/news/new-medscape-report-finds-more-than-one-in-three-doctors-are-burned-out/2476292/Burnout and depression are having a significant effect on the global medical community, as demonstrated by Medscape’s Global Physicians’ Burnout and Lifestyle Comparisons report. Nearly 20,000 doctors in six countries (France,
- Eyenovia Confirms Expanded MicroProst Phase 3 Indication to Enroll Broad Patient Population for IOP Loweringhttps://modernod.com/news/eyenovia-confirms-expanded-microprost-phase-3-indication-to-enroll-broad-patient-population-for-iop-lowering/2476294/Eyenovia confirmed a broad patient population for its phase 3 MicroProst program (microdose latanoprost with Optejet delivery) for the lowering of IOP. Following discussions with the FDA, the study population will include chronic a
- Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulationshttps://modernod.com/news/melt-pharmaceuticals-improves-patent-estate-for-sublingual-non-opioid-pain-and-sedation-formulations/2476298/Melt Pharmaceuticals, a specialty pharmaceutical company recently deconsolidated from Harrow Health, announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation formulations. U.S. Patents 10,16